Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats

Pharmacological Research

Volumn 41, Issue 1, 2000, Pages 31-37

  Al Shabanah, Othman A ^a   El Kashef, Hassan A ^a   Badary, Osama A ^a   Al Bekairi, Abdulla M ^a   Elmazar, Mohamed M A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cardiotoxicity; Doxorubicin; Hyperglycaemia; Pharmacokinetics; Rats

Indexed keywords

CREATINE KINASE; DOXORUBICIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CHRONOTROPISM; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEART ATRIUM; HEART RATE; HYPERGLYCEMIA; KIDNEY CLEARANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033986789     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0568     Document Type: Article

References (28)

1. Gwilt P R, Nahhas P R, Tracewell W G. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 20:1991;477-490.
2. O'Connor P, Feely J. Clinical pharmacokinetics and endocrine disorders. Clin Pharmacokinet. 13:1987;345-364.
3. Lee H J, Paik W H, Lee M G. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol. 89:1995;165-178.
4. Coudore F, Besson A, Courteix C, Eschalier A, Lavarenne J, Fialip J. P harmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites in streptozocin-induced diabetic rats. Gen Pharmacol. 27:1996;803-807.
5. Park K J, Yoon W H, Shin W G, Lee M G. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. J Pharm Pharmacol. 48:1996;1093-1097.
6. Sarangarajan R, Cacini W. Effect of route of administration and dose on diabetes-induced protection against cisplatin nephrotoxicity. Proc Soc Exp Biol Med. 212:1996;362-368.
7. Arcamone F. Properties of antitumour anthracyclines and new developments in their application. Cancer Res. 45:1985;5995-5999.
8. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J. 70:1993;499-502.
9. El-Kashef H A, Salem H A, Said S A, El-Mazar M M. Effect of praziquantel on serum glucose and insulin levels in normal and hyperglycemic rats. Arzneim-Forsch. 46:1996;433-435.
10. Rahman A, Ganjei A, Neef J R. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother Pharmacol. 16:1986;28-34.
11. Swanson J R, Wilkinson J H. Measurement of creatine kinase in serum. Cooper G R,. Standard Methods of Clinical Chemistry. 1972;33-42 Academic Press, NY:
12. Trinder P. Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J Clin Pathol. 22:1969;246.
13. Al-Khamees H A, Kandil H A, El-Tahir K EH, Bayomi S M. Synthesis and pharmacological activity of 3-[(p -acetamidoalkylbenzenesulfonyl]-thiazolidin-4-ones and thiazolines. Arch Pharm Res. 16:1993;186-190.
14. Mushlin P S, Cusack B J, Boucek R J, Andrejuk T, Li X, Olson R D. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol. 110:1993;975-982.
15. Renwick A G. Pharmacokinetics in toxicology. Hayes W,. Principles and Methods of Toxicology. 1982;659 Raven Press, NY:
16. Yesair D W, Schwartzbach E, Shuck D, Denine E P, Asbell M A. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res. 32:1972;1177-1182.
17. Maneiz-Devos D M, Baurain R, Trouet A, Lesne M. Doxorubicin pharmacokinetics in the rabbit. J Pharmacol. 16:1985;159-169.
18. Colombo T, Donelli M G, Urso R, Dallarda S, Bartosek I, Guaitani A. Doxorubicin toxicity and pharmacokinetics in old and young rats. Exp Gerontol. 24:1989;159-171.
19. Moroz L V, Kabieva A O, Donenko F V, Borovkova N B. Modification of doxorubicin action with artificial hyperglycaemia. Antibiot Khimioter. 35:1990;34-36.
20. Vora J, Boroujerdi M. Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: Prediction of butylated hydroxyanisol-mediated reduction in anthracycline cardiotoxicity. J Pharm Pharmacol. 48:1996;1264-1269.
21. Preus M, Bhargava A S, Khater A ER, Gunzel P. Diagnostic value of serum creatine kinase and lactate dehydrogenase isozyme determination for monitoring early cardiac damage in rats. Toxicol Lett. 42:1988;225-230.
22. Singal P K, Deally C M, Veinberg L E. Subcellular effects of adriamycin in the heart. J Mol Cell Cardiol. 19:1987;817-828.
23. 2+binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 250:1986;419-425.
24. Olson H M, Young D M, Prieur D J, Le Toy A F, Reagan R L. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 77:1974;439-454.
25. Doroshow J H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43:1983;460-472.
26. Bagchi D, Bagchi M, Hassoun E A, Kelly J, Stohs S J. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology. 95:1995;1-9.
27. Azuma J, Sperelakis N, Hasegawa H, Tanimoto T, Vogel S, Ogura K, Awata N, Sawamura A, Harada H, Ishiyama T, Morita Y, Yamamura Y. Adriamycin cardiotoxicity: possible pathogenic mechanisms. J Mol Cell Cardiol. 13:1981;381-397.
28. Kim D H, Landry A B, Lee Y S, Katz A M. Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol. 21:1989;433-436.